The first half of 2025 has brought major developments in gastroenterology, spanning new drug approvals, trial data, and clinical guidance. Two major FDA approvals expanded the use of IL-23-targeted therapies in Crohn’s disease: mirikizumab (Omvoh) and guselkumab (Tremfya), both showing strong clinical efficacy across trials.
Trending
- Behavioral Interventions Improve Mailed Colorectal Cancer Screening Among Overdue Patients in a Randomized Trial (CGH Journal)
- Leading efforts in insurance oversight (AGA)
- Different outcomes of AI-read vs human-read endoscopies in the TITRATE study (Medicom)
- Firefly-Inspired Pill Lights Up the Gut To Reveal Inflammation (Technology Networks)
- Private equity investment: Could it help physicians? (Medical Economics)
- Olympus execs talk about import alert, GI robot and AI (Medtech Dive)
- Breath Test for MASH/MASLD Shows Promise in Pilot Study (GI & Endoscopy News)
- With A Doctor Shortage; Is Concierge Medicine Morally Acceptable? (Forbes)
